Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia
Authors:
- Seemana BhattacharyaSBSeemana Bhattacharya
- Sujan PiyaSPSujan Piya
- Huaxian MaHMHuaxian Ma
- Priyanka SharmaPSPriyanka Sharma
- Qi ZhangQZQi Zhang
- Natalia BaranNatalia Baran
- Vivian R. RuvoloVRVivian R. Ruvolo
- Teresa McQueenTMTeresa McQueen
- R. Eric DavisRDR. Eric Davis
- Rasoul PourebrahimRPRasoul Pourebrahim
- Marina KonoplevaMKMarina Konopleva
- Hagop KantarjianHKHagop Kantarjian
- 14 February 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Research
- Vol. 21 (6) , 548-563
Abstract
Despite effective new therapies, adaptive resistance remains the main obstacle in acute myelogenous leukemia (AML) therapy. Autophagy induction is a key mechanism for adaptive resistance. Leukemic blasts at diagnosis express higher levels of the apical autophagy kinase ULK1 compared with normal hematopoietic cells. Exposure to chemotherapy and targeted agents upregulate ULK1, hence we hypothesize that developing ULK1 inhibitors may present the unique opportunity for clinical translation of autophagy inhibition. Accordingly, we demonstrate that ULK1 inhibition, by genetic and pharmacologic means, suppresses treatment-induced autophagy, overcomes adaptive drug-resistance, and synergizes with chemotherapy and emerging antileukemia agents like venetoclax (ABT-199). The study next aims at exploring the underlying mechanisms. Mechanistically, ULK1 inhibition downregulates MCL1 antiapoptotic gene, impairs mitochondrial function and downregulates components of the CD44-xCT system, resulting in impaired reactive oxygen species (ROS) mitigation, DNA damage, and apoptosis. For further validation, several mouse models of AML were generated. In these mouse models, ULK1 deficiency impaired leukemic cell homing and engraftment, delayed disease progression, and improved survival. Therefore, in the study, we validated our hypothesis and identified ULK1 as an important mediator of adaptive resistance to therapy and an ideal candidate for combination therapy in AML. Therefore, we propose ULK1 inhibition as a therapeutically relevant treatment option to overcome adaptive drug-resistance in AML. Implications: ULK1 drives a cell-intrinsic adaptive resistance in AML and targeting ULK1-mediated autophagy can synergize with existing and emerging AML therapies to overcome drug-resistance and induce apoptosis.Keywords
All Related Versions
Funding Information
- National Cancer Institute (CA016672)
- National Cancer Institute (P30CA016672)
- National Cancer Institute (1S10 RR09552)
- National Cancer Institute (CA16672)
- National Cancer Institute (P30CA030199)
This publication has 49 references indexed in Scilit:
- BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem CellsCell Stem Cell, 2013
- Autophagy: Renovation of Cells and TissuesCell, 2011
- Stem cell gene expression programs influence clinical outcome in human leukemiaNature Medicine, 2011
- The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTORAutophagy, 2011
- CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc− and Thereby Promotes Tumor GrowthCancer Cell, 2011
- AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1Nature Cell Biology, 2011
- Mechanisms of mitophagyNature Reviews Molecular Cell Biology, 2010
- Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cellsNature, 2010
- How mitochondria produce reactive oxygen speciesBiochemical Journal, 2008
- Ulk1 plays a critical role in the autophagic clearance of mitochondria and ribosomes during reticulocyte maturationBlood, 2008